FR21C1026I1 - SIMIEN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORS - Google Patents
SIMIEN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORSInfo
- Publication number
- FR21C1026I1 FR21C1026I1 FR21C1026C FR21C1026C FR21C1026I1 FR 21C1026 I1 FR21C1026 I1 FR 21C1026I1 FR 21C1026 C FR21C1026 C FR 21C1026C FR 21C1026 C FR21C1026 C FR 21C1026C FR 21C1026 I1 FR21C1026 I1 FR 21C1026I1
- Authority
- FR
- France
- Prior art keywords
- simien
- adenovirus
- adenoviral vectors
- hybrid adenoviral
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1108879.6A GB201108879D0 (en) | 2011-05-25 | 2011-05-25 | Vector |
| PCT/GB2012/000467 WO2012172277A1 (en) | 2011-05-25 | 2012-05-25 | Simian adenovirus and hybrid adenoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR21C1026I1 true FR21C1026I1 (en) | 2021-08-06 |
Family
ID=44279666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR21C1026C Active FR21C1026I1 (en) | 2011-05-25 | 2021-06-28 | SIMIEN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORS |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9714435B2 (en) |
| EP (2) | EP2714916B1 (en) |
| JP (1) | JP6230527B2 (en) |
| CN (1) | CN103930551B (en) |
| AU (1) | AU2012270144B2 (en) |
| BR (1) | BR112013030222A2 (en) |
| CA (1) | CA2837274C (en) |
| DK (1) | DK2714916T3 (en) |
| ES (1) | ES2659183T3 (en) |
| FR (1) | FR21C1026I1 (en) |
| GB (1) | GB201108879D0 (en) |
| NO (2) | NO2714916T3 (en) |
| RU (1) | RU2013152648A (en) |
| SG (2) | SG10201604179VA (en) |
| WO (1) | WO2012172277A1 (en) |
| ZA (1) | ZA201309016B (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| US9217159B2 (en) * | 2012-05-18 | 2015-12-22 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof |
| CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201413530D0 (en) | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
| EA038402B9 (en) * | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Adenovirus polynucleotides and polypeptides |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CN108699566B (en) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics |
| GB2549809C (en) * | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| CN110062630A (en) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | Cancer target synthesizes adenovirus and application thereof |
| CN106916851A (en) * | 2017-03-01 | 2017-07-04 | 广州恩宝生物医药科技有限公司 | Type adenovirus vector of a kind of replication deficient human 14 and its preparation method and application |
| CA3056542A1 (en) | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
| SG11201910101SA (en) | 2017-05-08 | 2019-11-28 | Gritstone Oncology Inc | Alphavirus neoantigen vectors |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| BR112020013679A2 (en) | 2018-01-04 | 2020-12-01 | Iconic Therapeutics, Inc. | antitecid factor antibodies, antibody-drug conjugates and related methods |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| CN109797168A (en) * | 2018-09-28 | 2019-05-24 | 广州佰芮慷生物科技有限公司 | A kind of expression vector SAd23-L of recombined adhenovirus |
| EP3863666A2 (en) | 2018-10-10 | 2021-08-18 | Oxford University Innovation Limited | Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same |
| GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
| CN109602901B (en) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | Herpes zoster virus vaccine and preparation method and application thereof |
| TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
| EP3972640A1 (en) | 2019-05-22 | 2022-03-30 | Gilead Sciences, Inc. | Combination of a tlr7 modulating compound and an hiv vaccine |
| CA3141454A1 (en) | 2019-05-22 | 2020-11-26 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| KR20220016137A (en) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | modified adenovirus |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| CA3161633A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| US20230075527A1 (en) | 2020-01-31 | 2023-03-09 | Janssen Pharmaceuticals, Inc | Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
| JP2023517286A (en) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | Compositions and methods for inducing an immune response |
| RU2720614C9 (en) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Immunobiological agent and a method for use thereof for inducing specific immunity against the sars-cov-2 severe acute respiratory syndrome virus (versions) |
| BR112022022937A2 (en) | 2020-05-11 | 2022-12-20 | Janssen Pharmaceuticals Inc | CORONAVIRUS PEAK PROTEIN STABILIZED FUSION PROTEINS |
| BR112022026408A2 (en) | 2020-06-29 | 2023-01-17 | Janssen Vaccines & Prevention Bv | VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION |
| EP4175971A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| KR20230046313A (en) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | Multi-epitope vaccine cassette |
| CA3152658A1 (en) * | 2020-08-22 | 2021-04-22 | Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation | Expression vector against severe acute respiratory syndrome virus sars-cov-2 |
| US20240050389A1 (en) | 2020-09-15 | 2024-02-15 | Imperial College Innovations Limited | Treatment of idiopathic pulmonary fibrosis |
| GB202016604D0 (en) | 2020-10-20 | 2020-12-02 | Univ Of Oxford | Compositions and methods for inducing an immune response |
| GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
| US20240033334A1 (en) * | 2020-12-04 | 2024-02-01 | Gritstone Bio, Inc. | Compositions and methods of use thereof |
| GB202019455D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for producing virus |
| GB202019454D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
| KR20230147156A (en) | 2021-02-19 | 2023-10-20 | 얀센 백신스 앤드 프리벤션 비.브이. | Stabilized pre-fusion RSV FB antigen |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| WO2022180007A1 (en) | 2021-02-23 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutation |
| JP2024511644A (en) | 2021-04-01 | 2024-03-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Stabilized prefusion PIV3 F protein |
| GB202105277D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
| WO2022234283A1 (en) | 2021-05-07 | 2022-11-10 | Astrazeneca Uk Limited | Compositions and methods for inducing an immune response |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023105221A1 (en) | 2021-12-07 | 2023-06-15 | Vaccitech (Uk) Limited | Vaccine boost methods and compositions |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3650939A (en) | 1964-11-12 | 1972-03-21 | Ppg Industries Inc | Alkali chlorine cell |
| CA2271450A1 (en) | 1999-05-12 | 2000-11-12 | Stuart Energy Systems Inc. | Hydrogen fuel replenishment process and apparatus |
| WO2003046124A2 (en) * | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| US7709026B2 (en) * | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
| US20070205342A1 (en) | 2002-01-23 | 2007-09-06 | Edward Gabriel | Slip drive for leveling devices |
| US7481858B2 (en) | 2005-02-25 | 2009-01-27 | Societe Bic | Hydrogen generating fuel cell cartridges |
| CA3028774A1 (en) * | 2004-01-23 | 2005-08-04 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
| US7617018B2 (en) | 2004-10-18 | 2009-11-10 | Innovative Design Solutions | Platform attitude adjustment augmentation method and apparatus |
| US7178337B2 (en) | 2004-12-23 | 2007-02-20 | Tassilo Pflanz | Power plant system for utilizing the heat energy of geothermal reservoirs |
| CN100578676C (en) * | 2005-01-12 | 2010-01-06 | 明基电通股份有限公司 | Adjustable lifting support apparatus |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| EP2152889B1 (en) * | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| BRPI0819783A2 (en) * | 2007-11-28 | 2015-06-23 | Univ Pennsylvania | Simian subfamily and adenovirus sadv-39, -25.2, -26, -30, -37 and -38 and uses thereof. |
| DK2406288T3 (en) * | 2009-03-10 | 2017-03-27 | Baylor Res Inst | ANTIGEN PRESENTING CELL-TARGETED VACCINES |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
-
2011
- 2011-05-25 GB GBGB1108879.6A patent/GB201108879D0/en not_active Ceased
-
2012
- 2012-05-25 JP JP2014511948A patent/JP6230527B2/en active Active
- 2012-05-25 AU AU2012270144A patent/AU2012270144B2/en active Active
- 2012-05-25 CA CA2837274A patent/CA2837274C/en active Active
- 2012-05-25 ES ES12723726.1T patent/ES2659183T3/en active Active
- 2012-05-25 US US14/119,413 patent/US9714435B2/en active Active
- 2012-05-25 WO PCT/GB2012/000467 patent/WO2012172277A1/en active Application Filing
- 2012-05-25 RU RU2013152648/10A patent/RU2013152648A/en not_active Application Discontinuation
- 2012-05-25 CN CN201280036659.1A patent/CN103930551B/en active Active
- 2012-05-25 NO NO12723726A patent/NO2714916T3/no unknown
- 2012-05-25 SG SG10201604179VA patent/SG10201604179VA/en unknown
- 2012-05-25 EP EP12723726.1A patent/EP2714916B1/en active Active
- 2012-05-25 BR BR112013030222A patent/BR112013030222A2/en not_active IP Right Cessation
- 2012-05-25 EP EP17204780.5A patent/EP3321367B1/en active Active
- 2012-05-25 DK DK12723726.1T patent/DK2714916T3/en active
- 2012-05-25 SG SG2013087747A patent/SG195181A1/en unknown
-
2013
- 2013-12-02 ZA ZA2013/09016A patent/ZA201309016B/en unknown
-
2017
- 2017-06-20 US US15/628,277 patent/US10646587B2/en active Active
-
2020
- 2020-04-15 US US16/849,301 patent/US11857640B2/en active Active
-
2021
- 2021-06-28 FR FR21C1026C patent/FR21C1026I1/en active Active
- 2021-07-07 NO NO2021028C patent/NO2021028I1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11857640B2 (en) | 2024-01-02 |
| US20200360533A1 (en) | 2020-11-19 |
| CA2837274A1 (en) | 2012-12-20 |
| AU2012270144B2 (en) | 2017-03-16 |
| SG195181A1 (en) | 2013-12-30 |
| JP2014516536A (en) | 2014-07-17 |
| EP2714916B1 (en) | 2018-01-10 |
| EP3321367B1 (en) | 2021-09-29 |
| NO2714916T3 (en) | 2018-06-09 |
| CN103930551A (en) | 2014-07-16 |
| EP3321367A3 (en) | 2018-07-25 |
| US20180000966A1 (en) | 2018-01-04 |
| ZA201309016B (en) | 2014-08-27 |
| WO2012172277A4 (en) | 2013-04-04 |
| JP6230527B2 (en) | 2017-11-15 |
| NO2021028I1 (en) | 2021-07-07 |
| EP3321367A2 (en) | 2018-05-16 |
| GB201108879D0 (en) | 2011-07-06 |
| CA2837274C (en) | 2021-05-25 |
| ES2659183T3 (en) | 2018-03-14 |
| CN103930551B (en) | 2017-05-24 |
| EP2714916A1 (en) | 2014-04-09 |
| RU2013152648A (en) | 2015-06-27 |
| DK2714916T3 (en) | 2018-02-19 |
| WO2012172277A1 (en) | 2012-12-20 |
| BR112013030222A2 (en) | 2016-12-06 |
| US10646587B2 (en) | 2020-05-12 |
| US9714435B2 (en) | 2017-07-25 |
| SG10201604179VA (en) | 2016-07-28 |
| US20150044766A1 (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1026I1 (en) | SIMIEN ADENOVIRUS AND HYBRID ADENOVIRAL VECTORS | |
| BR112013017629A2 (en) | recombinant laminin-521 | |
| BR112013015729A2 (en) | fixer | |
| DK2895102T3 (en) | IMPROVED VIRTUAL SHINE | |
| DK2542600T3 (en) | AROUND POLYURETHAND DISPERSIONS | |
| ES2667425T8 (en) | CMV recombinant glycoproteins and vectors | |
| DE112011103303B8 (en) | charging port | |
| BR302012006742S1 (en) | Tray Applied Configuration | |
| BR112013031066A2 (en) | buffer device | |
| BR302012005891S1 (en) | Tray Applied Configuration | |
| DK2567097T3 (en) | centrifugal | |
| EP2716756A4 (en) | Reic-expressing adenovirus vector | |
| DK2773241T3 (en) | FIXING DEVICE | |
| DK2932319T3 (en) | WAVEGUIDE ARRANGEMENT | |
| BR112014009793A2 (en) | railcar and railcar unloading set | |
| DE112011100920A5 (en) | galette | |
| FR2958525B1 (en) | SPONGE | |
| DK2627856T3 (en) | IMPROVED REDUCED DEVICE | |
| FI20115454A0 (en) | Adenoviral vectors and methods and uses relating thereto | |
| FI20115453A0 (en) | Adenoviral vectors and methods and uses relating thereto | |
| FI20105991A0 (en) | Adenovirus vectors and methods and uses therefor | |
| FI20105988A (en) | Adenoviral vectors and methods and uses relating thereto | |
| UA24063S (en) | BANKIVSKY ATM | |
| UA24062S (en) | BANKIVSKY ATM | |
| ES1072489Y (en) | COUPLER TRAY |